Johnson & Johnson (NYSE:JNJ) had its target price dropped by investment analysts at Credit Suisse Group from $154.00 to $151.00 in a note issued to investors on Friday. The firm presently has an “outperform” rating on the stock. Credit Suisse Group’s price target would indicate a potential upside of 19.22% from the company’s previous close.
Other research analysts also recently issued reports about the company. Vetr raised Johnson & Johnson from a “hold” rating to a “buy” rating and set a $150.89 price objective for the company in a research note on Thursday, January 11th. Leerink Swann reissued an “outperform” rating and issued a $160.00 price objective (down from $175.00) on shares of Johnson & Johnson in a research note on Wednesday. They noted that the move was a valuation call. Stifel Nicolaus reduced their price objective on Johnson & Johnson from $145.00 to $135.00 and set a “hold” rating for the company in a research note on Wednesday. Zacks Investment Research raised Johnson & Johnson from a “hold” rating to a “buy” rating and set a $145.00 price objective for the company in a research note on Wednesday, April 11th. Finally, Jefferies Group set a $161.00 price objective on Johnson & Johnson and gave the company a “buy” rating in a research note on Friday, March 23rd. Five analysts have rated the stock with a sell rating, eight have given a hold rating and ten have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average target price of $142.83.
Shares of JNJ stock opened at $126.66 on Friday. The company has a debt-to-equity ratio of 0.51, a current ratio of 1.41 and a quick ratio of 1.12. The company has a market cap of $342,204.16, a PE ratio of 17.35, a price-to-earnings-growth ratio of 1.97 and a beta of 0.74. Johnson & Johnson has a 1-year low of $121.54 and a 1-year high of $148.32.
In other Johnson & Johnson news, VP Paulus Stoffels sold 155,342 shares of the company’s stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $129.86, for a total value of $20,172,712.12. Following the completion of the sale, the vice president now directly owns 357,906 shares in the company, valued at approximately $46,477,673.16. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. 0.22% of the stock is owned by corporate insiders.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Green Square Capital LLC boosted its holdings in Johnson & Johnson by 35.5% during the 4th quarter. Green Square Capital LLC now owns 58,280 shares of the company’s stock valued at $8,143,000 after acquiring an additional 15,273 shares during the period. Cambridge Investment Research Advisors Inc. boosted its holdings in Johnson & Johnson by 6.4% during the 4th quarter. Cambridge Investment Research Advisors Inc. now owns 352,547 shares of the company’s stock valued at $49,258,000 after acquiring an additional 21,076 shares during the period. Certified Advisory Corp purchased a new position in Johnson & Johnson during the 4th quarter valued at about $2,751,000. Ackerman Capital Advisors LLC purchased a new position in Johnson & Johnson during the 4th quarter valued at about $1,447,000. Finally, Fairfield Bush & CO. boosted its holdings in Johnson & Johnson by 2.2% during the 4th quarter. Fairfield Bush & CO. now owns 44,871 shares of the company’s stock valued at $6,269,000 after acquiring an additional 955 shares during the period. Institutional investors and hedge funds own 67.23% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This news story was first posted by Week Herald and is the sole property of of Week Herald. If you are viewing this news story on another domain, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The correct version of this news story can be accessed at https://weekherald.com/2018/04/22/johnson-johnson-jnj-pt-lowered-to-151-00.html.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.